Enhancing our chances of picking a winner in higher‐risk myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18240
Abstract: Hypomethylating agents remain the current standard of care for patients with higher‐risk myelodysplastic syndromes. Adès et al. report outcomes from a randomised ‘pick‐a‐winner’ study design that examined the addition of either lenalidomide, valproic acid or… read more here.
Keywords: higher risk; myelodysplastic syndromes; winner; risk myelodysplastic ... See more keywords